However, some corroboration with our conclusions comes from the cancer literature, where genetic ablation of ATG4B or NSC185058 treatment has been show to slow cell growth in glioblastoma, while ATG4B knockout resulted in impaired mTORC1 activity in several cancer cell lines. This evidence concerns the gene ATG4B and glioblastoma.